REGENERON PHARMACEUTICALS, INC. Other Revenue, Net (Deprecated 2018-01-31)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Other Revenue, Net (Deprecated 2018-01-31) of $86.16 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Income Statement › Other Income
us-gaap:OtherSalesRevenueNet · last filed 2018-05-03
- REGENERON PHARMACEUTICALS, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $86.16M, a 52.65% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $107.07M, a 107.28% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $61.51M, a 128.10% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $113.50M, a 391.34% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2017 was $338.52M, a 184.23% increase from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2016 was $119.10M, a 59.04% increase from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2015 was $74.89M, a 134.46% increase from fiscal 2014.
- REGENERON PHARMACEUTICALS, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2014 was $31.94M.
| Period end | Other Revenue, Net (Deprecated 2018-01-31) 3 month | Other Revenue, Net (Deprecated 2018-01-31) 6 month | Other Revenue, Net (Deprecated 2018-01-31) 9 month | Other Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $86.16M 10-Q · filed 2018-05-03 | $193.23M derived: sum of 2 quarters · filed 2018-05-03 | $254.74M derived: sum of 3 quarters · filed 2018-05-03 | $368.24M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-12-31 | $107.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $168.58M derived: sum of 2 quarters · filed 2018-02-08 | $282.08M derived: sum of 3 quarters · filed 2018-02-08 | $338.52M 10-K · filed 2018-02-08 |
| 2017-09-30 | $61.51M 10-Q · filed 2017-11-08 | $175.01M derived: sum of 2 quarters · filed 2017-11-08 | $231.45M 10-Q · filed 2017-11-08 | $283.10M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-06-30 | $113.50M 10-Q · filed 2017-08-03 | $169.94M 10-Q · filed 2017-08-03 | $221.60M derived: sum of 3 quarters · filed 2018-05-03 | $248.56M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-03-31 | $56.44M 10-Q · filed 2018-05-03 | $108.10M derived: sum of 2 quarters · filed 2018-05-03 | $135.06M derived: sum of 3 quarters · filed 2018-05-03 | $158.16M derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $51.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $78.62M derived: sum of 2 quarters · filed 2018-02-08 | $101.72M derived: sum of 3 quarters · filed 2018-02-08 | $119.10M 10-K · filed 2018-02-08 |
| 2016-09-30 | $26.96M 10-Q · filed 2017-11-08 | $50.06M derived: sum of 2 quarters · filed 2017-11-08 | $67.44M 10-Q · filed 2017-11-08 | $85.52M derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-06-30 | $23.10M 10-Q · filed 2017-08-03 | $40.48M 10-Q · filed 2017-08-03 | $58.55M derived: sum of 3 quarters · filed 2018-02-08 | $76.08M derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-03-31 | $17.38M 10-Q · filed 2017-05-04 | $35.45M derived: sum of 2 quarters · filed 2018-02-08 | $52.98M derived: sum of 3 quarters · filed 2018-02-08 | $64.43M derived: sum of 4 quarters · filed 2018-02-08 |
| 2015-12-31 | $18.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $35.60M derived: sum of 2 quarters · filed 2018-02-08 | $47.05M derived: sum of 3 quarters · filed 2018-02-08 | $74.89M 10-K · filed 2018-02-08 |
| 2015-09-30 | $17.53M 10-Q · filed 2016-11-04 | $28.98M derived: sum of 2 quarters · filed 2016-11-04 | $56.82M 10-Q · filed 2016-11-04 | |
| 2015-06-30 | $11.45M 10-Q · filed 2016-08-04 | $39.29M 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $27.84M 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $31.94M 10-K · filed 2017-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |